RxDoctor Payments Data

Svetlana Barbarash, MD

Cardiovascular Disease · Las Vegas, NVNPI 1417927500

Payments from drug & device makers

$2,012in general payments, 2019–2025

Across 32 payments — averaging $62.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$507
  • Heartflow, Inc.$362
  • E.r. Squibb & Sons, L.L.C.$269
  • Boehringer Ingelheim$244
  • Abbott$164
  • Inspire Medical Systems, Inc.$139
  • plus $327 from 7 others

What the payments were for

  • Food & beverage$2,012100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,012 in reported general payments places this provider in the 35th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$35,147
Medicare patients
159
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban394$375,602
EntrestoSacubitril/Valsartan111$126,193
JardianceEmpagliflozin89$109,147
XareltoRivaroxaban76$82,668
Praluent PenAlirocumab17$8,813
Repatha SureclickEvolocumab12$6,718
Atorvastatin Calcium518$5,223
Metoprolol Succinate519$4,854
Carvedilol175$1,416
Rosuvastatin Calcium152$1,323
Isosorbide Mononitrate ErIsosorbide Mononitrate76$1,283
Amlodipine Besylate169$1,260
Losartan Potassium142$1,158
Furosemide144$1,039
Torsemide44$986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$375,602394 claims
Boehringer IngelheimJardiance$244$109,14789 claims
Johnson & JohnsonXarelto$507$82,66876 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →